Vimarsana
Biggest News Aggregation in the World

Page 41 - Ascular News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ascular. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ascular Today - Breaking & Trending Today

Microbot Medical's LIBERTY® Robotic System Surpasses 100th Catheterization - Vimarsana News

Microbot Medical's LIBERTY® Robotic System Surpasses 100th Catheterization

95% success rate of reaching pre-determined vascular target with no intraoperative complications presented during pre-clinical studiesHINGHAM, Mass., May 03, 2023 -- Microbot Medical Inc. , the... | May 3, 2023

Urgent call for improved diagnostics, treatments, and vaccines against deadly Hantavirus - Vimarsana News

Urgent call for improved diagnostics, treatments, and vaccines against deadly Hantavirus

Scientists discuss hantavirus infections, which are a type of viral hemorrhagic fever that can be transmitted to humans through exposure to infected rodents in endemic areas.

What are the benefits of exercise on cardiovascular health? - Vimarsana News

What are the benefits of exercise on cardiovascular health?

Researchers estimated the impact of exercise on cardiovascular (CV) health.

Expression profiles and roles of cardiac pigment epithelium-derived factor during cardiac development - Vimarsana News

Expression profiles and roles of cardiac pigment epithelium-derived factor during cardiac development

Announcing a new article publication for Cardiovascular Innovations and Applications journal. This paper describes the expression profiles and roles of cardiac pigment epithelium-derived factor (PEDF) during cardiac development.

Xeltis presents excellent six-month first-in-human data from aXess hemodialysis vascular graft trial at Vascular Access Society Congress - Vimarsana News

Xeltis presents excellent six-month first-in-human data from aXess hemodialysis vascular graft trial at Vascular Access Society Congress

Xeltis presents excellent six-month first-in-human data from aXess hemodialysis vascular graft trial at Vascular Access Society Congress aXess graft demonstrated excellent patency